CHMP Recommends EU Approval of Lilly's Oral GLP-1 Pill Foundayo for Obesity and Type 2 Diabetes

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended granting an EU marketing authorisation for Eli Lilly's Foundayo (orforglipron), an oral GLP-1 receptor agonist, for weight management and treatment of type 2 diabetes in adults, according to an EMA news release. The positive opinion marks a step toward broader European availability of a pill-form alternative to injectable GLP-1 therapies.

Seeking Alpha reported that the endorsement from the EU drug regulator's expert panel paves the way for approval in a market where, the outlet said, rival Novo Nordisk currently holds the first-mover advantage.

What CHMP Recommended

According to EMA, Foundayo is recommended for weight management and for type 2 diabetes in adults. For diabetes specifically, the agency said the medicine is intended for use alongside a healthy diet and physical activity in adults whose blood glucose levels are not sufficiently controlled, and it can be used alone when metformin is not appropriate or together with other diabetes medicines.

EMA described Foundayo as a prescription-only tablet taken once daily, which can be taken at any time of day, with or without food. Treatment starts at a low dose that is gradually increased based on how the patient responds and tolerates the medicine. The agency noted the applicant for Foundayo is Eli Lilly Nederland B.V.

How the Drug Works

The active substance, orforglipron, is described by EMA as a small, non-peptide molecule that activates the GLP-1 receptor. By activating this receptor, the agency said, orforglipron reduces appetite and increases feelings of fullness, helping people eat less and lose weight, while also contributing to blood glucose control.

Clinical Evidence Behind the Opinion

EMA said its recommendation for weight management is based on two studies involving more than 4,740 adults with obesity or overweight. After 72 weeks, the agency reported, participants treated with Foundayo lost around 5% to 11% of their body weight depending on the dose taken, compared with around 2% to 2.5% in those who took placebo.

Those figures come directly from EMA's published summary. The 5% to 11% range reflects the different doses studied rather than a single result, with higher doses associated with greater weight loss, and it describes total weight loss among participants taking Foundayo — not a placebo-adjusted figure. EMA reported the placebo comparison separately at around 2% to 2.5% of body weight after 72 weeks.

Safety Profile

The most common side effects reported with Foundayo were nausea, vomiting and diarrhoea, EMA said, which occurred more often while the dose was being increased and became less frequent over time. The agency's public statement did not describe additional risk-management conditions or specific organ-safety warnings beyond this gastrointestinal tolerability profile.

Path to Approval and Market Context

EMA was explicit that the CHMP opinion is an intermediary step rather than a final approval. The opinion now goes to the European Commission, which will decide whether to grant an EU-wide marketing authorisation. Once that authorisation is granted, EMA said, decisions on price and reimbursement will be made individually by each EU member state, taking into account the medicine's potential role within that country's national health system. EMA's release did not specify a target date for the Commission's decision or detail any EU manufacturing or supply commitments from Lilly.

EMA framed the potential significance of the medicine against the scale of the underlying health problems it targets, noting that obesity and overweight affect more than 2.5 billion people worldwide, and that diabetes affects approximately 589 million adults aged 20 to 79, with type 2 diabetes accounting for about 90% of all cases.

Competitive Backdrop

Seeking Alpha's reporting framed the CHMP opinion within a competitive context, noting that Lilly is pursuing the European obesity and diabetes market where Novo Nordisk currently holds what the outlet called a first-mover advantage. The evidence reviewed here does not include head-to-head efficacy, dosing or pricing comparisons between Foundayo and Novo Nordisk's products in Europe, nor analyst estimates of peak European sales for Foundayo; any such comparisons would require reporting beyond what EMA and Seeking Alpha have disclosed so far.

Bottom Line

The CHMP's positive opinion is a meaningful regulatory milestone for Lilly's oral GLP-1 candidate in Europe, but it is not yet a final approval. The European Commission must still issue a formal decision on EU-wide authorisation, after which individual member states will separately determine pricing and reimbursement. Investors and patients watching this story should treat the current stage as a recommendation, not a confirmed market launch, pending the Commission's decision and national-level access decisions that typically follow.